Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

Inclusion Criteria: * All patients with primary, previously untreated, histologically confirmed invasive carcinoma of the vulva (any cell type) not amenable to surgical excision. Clinical stages T2-T4, N0-3, M0. Hematoxylin \& eosin (H \& E) stained slide showing documentation of the primary invasive cancer is required. All specimens of primary tumor require documentation of type * Absolute neutrophil count (ANC) \>= 1,500/microliter (performed within 28 days from signing consent form) * Platelet count \>= 100,000/microliter (performed within 28 days from signing consent form) * Creatinine \< 2.0 mg/dL (performed within 28 days from signing consent form) * Total bilirubin =\< 1.5 times normal (performed within 28 days from signing consent form) * Glutamic-oxaloacetic transaminase (SGOT) =\< 3 times normal (performed within 28 days from signing consent form) * Patients with an Eastern Cooperative Oncology Group/Gynecologic Oncology Group (ECOG/GOG) performance status of 0, 1, or 2 * Patients with ureteral obstruction must be treated with stent or nephrostomy tube * Patients must be consented within twelve (12) weeks of diagnosis or must be restaged * Patients of childbearing potential must use an effective form of birth control. "Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive measures should be used during therapy with VIRACEPT." * Confirmed seronegative HIV status within 3 months of signing consent * Patients must have …